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Background. Atherosclerosis has been assessed in human immunodeficiency virus (HIV)–infected persons by
using various methods. Peripheral arterial disease (PAD) has not been evaluated, however. We studied the cross-
sectional prevalence of lower limb PAD in an HIV-infected population.
Methods. PAD was assessed using the Edinburgh Claudication Questionnaire and by measuring the systolic
ankle-brachial blood pressure index (ABI) at rest and after exercise. Patients with PAD were further evaluated by
duplex scan of lower limb arteries.
Results. Ninety-two consecutive HIV-infected patients were evaluated (23.9% women; mean age, 49.5 years;
61.9% current smokers). Claudication was reported by 15.2% of the patients. PAD was found in 20.7% of the
patients: 9.8% had an abnormal ABI (!0.90) at rest, and 10.9% had normal ABI at rest but a 125% decrease after
exercise. Of the patients with PAD, 84.2% were investigated with duplex scan, all of whom had atherosclerotic
occlusions or stenoses of the iliac or femoral arteries. Age, diabetes, smoking, and low CD4+ T lymphocyte counts
were identified as independent predictors of PAD.
Conclusions. The prevalence of symptomatic and asymptomatic PAD is high in the HIV-infected population
and is much higher than expected (prevalence in the general population, ∼3% at 60 years). This study suggests
the presence of an epidemic of PAD ∼20 years earlier in the HIV-infected than in the general population. Larger
epidemiological studies are needed to better define risk factors and to evaluate whether PAD is associated with
increased mortality, as it is in the general population.
Combination antiretroviral therapy has dramatically de-
creased the mortality and illnesses related to HIV infec-
tion. However, a variety of atherogenic metabolic ab-
normalities, including dyslipidemia, lipodystrophy, and
insulin resistance [1, 2], have been observed soon after
the introduction of combination antiretroviral therapy.
Concern about increased cardiovascular mortality was
raised by the detection of subclinical atherosclerosis by
measuring the carotid intima-media thickness [3–5], en-
dothelial dysfunction [6, 7], and coronary calcifications
[8]. An association between premature coronary events
and use of protease inhibitors (PIs) is now well estab-
lished in the HIV-infected population [9, 10].
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The prevalence of peripheral arterial disease (PAD)
has not been assessed in HIV-infected patients. In the
general population, PAD is associated with traditional
cardiovascular risk factors, particularly smoking, dia-
betes, hypertension, and hypercholesterolemia [11].
These factors may have an increased prevalence among
HIV-infected patients [10, 12]. PAD of the lower limbs
can be assessed by a marker validated in numerous
studies, the ankle-brachial index (ABI) [11]. A de-
creased ABI is associated with a shorter survival in the
general population, which is mainly due to an increase
in coronary and cerebrovascular events [13, 14]. The
aim of our study was to assess the cross-sectional prev-
alence of PAD in an HIV-infected population and to
evaluate the feasibility of measuring the ABI in the
routine HIV care setting.
a Present affiliation: Infectious Diseases Service, University Hospital, Bruderholz,
Switzerland.
b Members of the SHCS are listed at the end of the text.
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Table 1. Clinical characteristics of the 92 study participants, compared with the 511
patients aged 40 years observed in the outpatient HIV clinic of the University Hospital







Male 70 (76.1) 357 (69.9)
Age, mean years  SD 49.5  7.4 49.7  7.9
Ethnicity
White 81 (88.0) 448 (87.7)
Black 7 (7.6) 44 (8.6)
Other 4 (4.3) 19 (3.7)
Presumed mode of HIV transmission
Heterosexual sex 27 (29.3) 224 (43.8)
Homosexual sex 37 (40.2) 182 (35.6)
Injection drug use 26 (28.3) 88 (17.2)
Other 2 (2.2) 17 (3.3)
HIV load !400 copies/mL 73 (79.3) 387 (75.7)
CD4+ T cell count, cells/mL
!200 5 (5.4) 46 (9.0)
200–500 35 (38.0) 218 (42.7)
1500 51 (55.4) 246 (48.1)
Family history of cardiovascular disease 21 (22.8) 93 (18.2)
Hypertension 25 (27.2) 153 (29.9)
Diabetes mellitus 4 (4.3) 33 (6.5)
Increased plasma non-HDL cholesterol levela 12 (13.0) 62 (12.1)
Low plasma HDL cholesterol levelb 16 (17.4) 109 (21.3)
Elevated plasma triglyceride levelc 33 (35.9) 134 (26.2)
Metabolic syndrome 25 (27.2) NA
Current smoking 57 (62.0) 197 (38.6)
NOTE. Data are no. (%) of patients, unless otherwise indicated. HDL, high-density lipoprotein; NA, not
available.
a Defined as a level 14.9 mmol/L.
b Defined as a level !1.03 mmol/L.
c Defined as a level 12.26 mmol/L.
METHODS
Patients. From 1 July through 30 September 2006, all con-
secutive HIV-infected patients aged 40 years who were ob-
served in the Infectious Disease Outpatient Clinic at the Uni-
versity Hospital in Lausanne, Switzerland, were invited to take
part to the study. The only exclusion criteria were active in-
jection drug use or known arterial complications from previous
use. Informed consent was obtained from all patients, and the
study was approved by the institutional ethics committee.
Symptoms potentially related to PAD (claudication, rest pain,
and nonhealing leg wounds) were recorded using the Edin-
burgh Claudication Questionnaire [15].
Cardiovascular risk factors. Abnormal plasma lipid levels
were defined using the third adult treatment panel guidelines
of the National Education Cholesterol Program [16]. To take
into account the longitudinal variability in lipid levels due to
changes of combination antiretroviral therapy, lipid-lowering
medication, and fasting status, we considered, in addition to
the point prevalence of dyslipidemia at the most recent blood
draw, the longitudinal prevalence of sustained dyslipidemia,
as previously reported [17], by including all lipid levels de-
termined during the 5-year period preceding the ABI mea-
surement. Sustained non–high-density lipoprotein (HDL)
hypercholesterolemia, low HDL cholesterol levels, and hy-
pertriglyceridemia were defined as more than two-thirds of
an individual patient’s respective measurements in plasma
being 14.9 mmol/L (190 mg/L), !1.03 mmol/L (40 mg/L),
and 12.26 mmol/L (200 mg/L), respectively. Hypertension was
defined as a brachial blood pressure of 1140/90 mm Hg, as
measured after 5 min of rest, or by the current use of any
antihypertensive drug. Metabolic syndrome was defined by
the International Diabetes Federation criteria [18].
Rest and postexercise ABI measurement. Patients rested
for 5 min lying on a bed, after which blood pressure was mea-
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Figure 1. Distribution of abnormal ankle-brachial blood pressure index
(ABI) values at rest and after exercise according to symptoms.
sured at the posterior tibialis and dorsalis pedis arteries of both
ankles with a 5.0 MHz vascular Nicolet Elite Doppler probe
(Viasys) and a sphygmomanometer. Brachial pressure was si-
multaneously measured at both arms by 2 HEM-907 automated
manometers (Omron), with cuff size adapted to the arm cir-
cumference. For each leg, the ABI was calculated by dividing
the higher systolic ankle pressure by the higher brachial systolic
pressure. The ABI threshold of 0.90, measured at rest, has 79%
sensitivity and 96% specificity to detect stenoses of 50% re-
duction in arterial luminal diameter [19]. To evaluate the pres-
ence of presumably less severe arterial stenoses that were not
detected at rest, the same ABI measurement was repeated im-
mediately after the patient slowly performed 20 squats, under
supervision. Among the different exercise protocols used to
confirm or quantify PAD [20], we chose squatting because it
is simple to perform and does not require a mechanical tread-
mill. PAD was investigated by the same ABI measures in a
control group of HIV-uninfected subjects. These subjects were
recruited among hospital coworkers if they were current smok-
ers and were aged 40 years.
Definition of PAD. According to the American Heart As-
sociation and American College of Cardiology guidelines, PAD
was diagnosed when the ABI was !0.90 at rest or when the
ABI significantly decreased after exercise [11]. Different thresh-
olds to define an exercise-related ABI decrease have been used
in different studies [21–23]. Considering the intra-observer var-
iability of ABI measurement (estimated to be 0.06–0.08) [24],
an absolute decrease in ABI of 10.15 (2 SDs) is usually con-
sidered to be significant [11]. To increase specificity, we defined
a postexercise decrease of 125% as significant.
Duplex scan. To confirm and localize vascular lesions, pa-
tients with abnormal rest or postexercise ABI were invited to
undergo arterial duplex scanning (En Visor HD; Philips Ul-
trasounds). The wall and lumen of the main arteries from the
abdominal aorta to the ankles were evaluated. Plaque was de-
fined as 11.2-mm thickening of the intima-media of the arterial
wall, with or without calcifications. The percentage of stenosis
was estimated by the peak systolic velocity ratio [25]. All ABI
measurements and duplex scans were performed by 1 of 3
vascular specialists (D.P., M.C., or D.H.).
Statistical analysis. The contribution of clinical charac-
teristics, cardiovascular risk factors (hypertension, smoking, di-
abetes, plasma lipid levels, and metabolic syndrome), and in-
fectious parameters (most recent CD4+ T cell count, most
recent HIV load, duration of seropositivity, and cumulative
exposure to PIs and nonnucleoside reverse-transcriptase inhib-
itors) to prevalence of PAD were analyzed using multivariable
logistic regression analysis. Factors were first analyzed individ-
ually in bivariate analysis and then selected for multivariable
analysis on the basis of a P value !.2 or a confounding effect.
Linearity on the logit scale was assessed with the fractional
polynomial method. Because of the limited sample size, no
more than 4 factors were assessed at any time. Goodness of fit
was determined using the Hosmer Lemeshow test and area
under the receiver operating curve. All statistical analyses were
performed using Stata software, version 9.2 (Stata).
RESULTS
Patients. Ninety-two patients (23.9% women) were included
in the study. Their clinical characteristics were compared with
those of the remaining 511 HIV-infected patients aged 40
years who were observed in our clinic in 2006 but did not
participate in the study (table 1). Claudication (grade 1 and 2
of Edinburgh Questionnaire) was reported by 15.2% of the
patients. No patient reported leg pain at rest or nonhealing leg
ulcers.
ABI results are shown in figure 1. PAD was found in 20.7%
(95% CI, 12.2%–29.1%) of the patients: 9.8% (95% CI, 3.6%–
16.0%) had an abnormal ABI at rest, and 10.9% (95% CI,
4.4%–17.4%) had a normal rest ABI but a 125% decrease after
exercise. All 9 patients with rest ABI of !0.90 also had a post-
exercise ABI decrease of 125% (mean decreaseSD, 34.1%
20.0%). Among the 15.2% of patients reporting claudication
of the lower limbs, 6.5% had normal ABI results, 6.5% had
decreased ABI at rest, and 2.2% had a normal rest ABI but an
abnormal ABI after exercise.
Duplex scan revealed classical atherosclerotic occlusive dis-
ease of the iliac and femoral arteries in all 9 patients with rest
ABI of !0.90 (table 2). Among the 10 patients with rest ABI
of 0.90 and 125% decrease after exercise, 7 agreed to duplex
scanning. Atherosclerotic plaques or stenoses were found in all
7 patients (table 3).
Among the 9 patients with rest ABI of !0.90, 2 had known
coronary disease, 1 had a previous stroke due to carotid dis-
section, and 5 had no known history of cerebral or coronary
vascular disease. One patient gave a history of exercise-related
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after exercise Duplex scan findings
1 M 77 After 200 m None 0.77 0.55 Femoropopliteal and calf atherosclerosis
2 M 68 After 50 m Diabetes, cholesterol 0.71 0.48 Diffuse aorto-iliac, femoropopliteal and calf
atherosclerosis
3 M 66 None Diabetes 0.81 0.63 Diffuse aorto-iliac, femoropopliteal, and calf
atherosclerosis
4 M 56 After 150 m Hypertension, choles-
terol, smoking
0.82 0.42 Diffuse aorto-iliac, femoropopliteal, and calf
atherosclerosis
5 M 56 After 50 m Smoking, hypertension,
cholesterol
0.79 0.48 95% Stenosis of the left common iliac artery
6 M 46 After 150 m Smoking 0.65 0.45 Bilateral occlusion of the popliteal arteries
7 M 45 After 100 m Smoking, cholesterol 0.70 0.32 90% Stenosis of the left and occlusion of the right com-
mon iliac arteries
8 F 42 After 80 m Smoking 0.74 0.44 Diffuse aorto-iliac atherosclerosis with 95% stenosis of
the left common iliac artery
9 F 40 After 200 m Smoking 0.55 0.20 Diffuse aorto-iliac atherosclerosis with occlusion of the
left extern iliac artery
a Distance of walk after which symptoms appear in the lower limbs.
chest pain, which occurred at the time of preanesthesia eval-
uation before peripheral artery bypass surgery. Among the 10
patients with rest ABI of 0.90 and 125% decrease after ex-
ercise, one had known coronary artery disease.
Controls. Thirty-two HIV-uninfected, currently smoking
control subjects (mean age, 47 years; range, 41–56 years) were
included. Four (12.5%) had hypertension. None had a rest ABI
of !0.90, and 2 (6.3%) had a 125% decrease after exercise.
Predictors of PAD. Results of logistic regression analysis
are shown in table 4. In bivariate analysis, a correlation was
found between PAD and age, smoking, hyperlipidemia, diabetes
mellitus, hypertension, metabolic syndrome, family history of
cardiovascular disease, and CD4+ T cell count of !200 cells/
mL. Other factors related to HIV infection (duration of sero-
positivity, clinical stage, and cumulative exposure to PIs) had
ORs that suggested a correlation with PAD but that did not
reach statistical significance. Multivariate analysis identified age,
smoking, diabetes, and CD4+ T cell of !200 cells/mL as im-
portant and significant predictors of PAD (table 4). The fit of
this model was satisfactory (area under receiver operating curve,
0.78; sensitivity, 67%; specificity, 62%; , by HosmerPp .58
Lemeshow test). Dyslipidemia, metabolic syndrome, and fa-
milial history had ORs that were 2.0 but did not reach sig-
nificance in multivariable analysis.
DISCUSSION
The major finding of this pilot study is a high cross-sectional
prevalence of PAD in a population representative of HIV-in-
fected persons in western Europe. PAD was evaluated using
widely accepted definitions and screening tools, and duplex
scan confirmed atherosclerotic disease of the main limb arteries
in all patients with an abnormal ABI either at rest or after
exercise. Atherosclerotic lesions were localized in the iliac and
femoral arteries, as generally seen in nondiabetic patients with
PAD. Most patients with PAD had symptoms limited to ex-
ertion, and no study participant had ischemic rest pain or
critical limb ischemia, consistent with the relatively young age
of participants. Duplex scan identified more-severe atheroscle-
rotic disease in patients with abnormal rest ABI than in those
with decreased ABI after exercise only. Only 5 of the 19 patients
with PAD were previously known to have cerebral or coronary
vascular disease, potentially allowing the 14 newly identified
patients with PAD to receive interventions to correct modifiable
cardiovascular risk factors.
Large epidemiological studies have reported a prevalence of
PAD of ∼1% at 50 years and 3% at 60 years of age in the
general population [26, 27]. The 20.7% prevalence of PAD in
our study, evaluating a relatively young population of HIV-
infected patients (median age, 49.5 years), is therefore strikingly
higher than expected. This difference with historical control
subjects may be attributed in part to technical differences in
the method used to screen for PAD. Most large population
studies have used rest ABI of !0.90 as the definition of PAD.
In our study, the systematic performance of a second ABI after
exercise raised the sensitivity of screening and doubled the pro-
portion of patients with PAD. The utility of this exercise was
demonstrated by duplex scan confirmation of PAD in all pa-
tients (including those whose ABI decreased only after exercise).
However, even if we consider only the proportion of patients
who had rest ABI of !0.90 in our study (9.8%), this proportion
remains considerably higher than that for historical control
subjects aged !50 years.
A high proportion of patients included in the study were
smokers, which may have contributed to the high proportion
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Table 3. Clinical characteristics and duplex scan findings of 7 patients with ABI of 0.90 at rest and a 125% decrease after exercise.
Patient Sex
Age,




after exercise Duplex scan findings
1 M 55 None Smoking, cholesterol 1.08 0.79 Common femoral and superficial femoral atherosclerotic plaque
2 M 54 After 300 m Smoking 0.92 0.69 Bilateral stenosis of the superficial femoral arteries
3 M 49 None Smoking, cholesterol 1.25 0.87 Common femoral and superficial femoral atherosclerotic plaque
4 M 44 None Smoking 1.12 0.84 Common femoral and superficial femoral atherosclerotic plaque
5 M 44 None Smoking, cholesterol 1.19 0.89 Atherosclerotic plaques in the iliac and femoral arteries
6 M 40 After 150 m Smoking, diabetes 1.16 0.72 Common femoral and superficial femoral atherosclerotic plaque
7 F 40 None Smoking 1.23 0.87 Superficial femoral atherosclerotic plaque
a Distance of walk after which symptoms appear in the lower limbs.
of PAD detected. However, smoking alone cannot fully explain
the high PAD prevalence, because 3 of the 9 HIV-infected pa-
tients with rest ABI of !0.9 were nonsmokers and because only
2 (6.3%) of the 32 HIV-uninfected control subjects, all of whom
were smokers, had PAD. This is consistent with the results of
a study of HIV-seronegative men aged 45–50 years, 72.3% of
whom were current or past smokers, which found a prevalence
of PAD of 1% [26].
Considerable attention has been paid in the literature to the
effect of combination antiretroviral therapy on premature ath-
erosclerosis of the coronary or carotid arteries [3–9]. Never-
theless, to our knowledge, the incidence of PAD of the lower
limbs has not been investigated in the HIV-infected population.
Subclinical atherosclerosis was found in several studies using
by B-mode ultrasound on the carotid or femoral arteries, in-
dicated by either an increase in intima-media thickness or the
presence of plaques [3, 4, 28–31]. Depairon et al. [4] found
that 55% of HIV-infected patients had at least 1 carotid or
femoral plaque, compared with 38% of healthy control subjects.
Maggi et al. [3] found an increased proportion of carotid
plaques or thickened intima-media thickness in HIV-infected
patients treated with PIs, compared with the proportion among
PI-naive patients and healthy control subjects. They also found
a more rapid onset of new lesions and a more rapid thickening
of previous lesions in patients treated with PIs than in patients
treated with nonnucleoside reverse-transcriptase inhibitors
[28]. Sevastianova et al. [32] found that prolonged PI exposure
was associated with increased peripheral arterial stiffness mea-
sured by pulse wave velocity. Van Wijk et al. [7] found that
HIV-infected patients had decreased flow-mediated vasodila-
tion but a normal pulse wave velocity. All of these findings are
considered to be the first measurable manifestations of ather-
osclerosis at various stages in a process leading to peripheral
arteriopathy. Most of these markers of atherosclerosis are as-
sociated with an increased cardiovascular mortality or are pu-
tative markers of concomitant coronary disease in the general
population.
Several possible mechanisms might be responsible for pre-
mature development of PAD in the HIV-infected population.
First, HIV-infected patients tend to have lifestyle-related car-
diovascular risk factors, including a high prevalence of smoking,
as identified in our study. Second, combination antiretroviral
therapy–related dyslipidemia, lipodystrophy, and impaired glu-
cose tolerance may be associated with the development of pre-
mature atherosclerosis, as previously shown [3, 4, 28, 29, 32–
35], even though an association between PI exposure and
vascular disease was not consistently identified [30, 31]. This
discrepancy might be explained by the mechanisms by which
PIs are supposed to be atherogenic. PIs are associated with
usually reversible dyslipidemia, and long-term exposure to PIs
is probably necessary for atherosclerosis to develop, whereas a
short duration of PI exposure may temporarily modify lipid
levels without substantial development of atherosclerosis.
Moreover, not all patients develop dyslipidemia on exposure
to PIs. This may have been illustrated in our study by the weak
association between PAD and PI use, whereas the association
with dyslipidemia was stronger. In our study, PI use was as-
sociated with a slight increase (OR, 1.03; ) in PAD risk,Pp .6
per additional year of exposure. Nevertheless, sustained dysli-
pidemia, which is attributable predominantly to PI use in this
young patient population, was associated with larger ORs for
PAD (for non-HDL hypercholesterolemia: OR, 2.94; ;Pp .15
for hypertriglyceridemia: OR, 2.98; ). This suggests thePp .20
presence of an association between PIs and PAD that needs
further clarification. Larger studies with many more patients
will be necessary to confirm the role of PIs and to evaluate
potential associations of other antiviral agents with PAD.
A third hypothetical mechanism could be a direct HIV injury
to the arterial wall, resulting in inflammatory lesions, as recently
suggested by Maggi et al. [36]. This is illustrated by the ectatic
or aneurysmal dilation of large arteries observed in HIV-in-
fected children. Lai et al. [37] reported aortic root dilations in
children aged 2–9 years with vertically transmitted HIV infec-
tion. The aortic root size was associated with left ventricular
dilation, increased viral load, and lower CD4+ T cell count.
Dubrovsky et al. [38] reported the cases of 13 HIV-infected
children with cerebral artery aneurysms. The etiology of these
aneurisms remains unknown, but vasculitis, either infectious
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OR (95% CI) P OR (95% CI) P
Sex (male vs. female) 3.20 (0.67–15.5) .14 1.24 (0.22–6.85) .81
Age (per additional year) 1.07 (1.00–1.15) .04 1.09 (1.00–1.18) .04
Smoking (per additional 10 pack-year) 1.30 (0.99–1.70) .05 1.70 (1.17–2.46) .005
Diabetes mellitus 13.5 (1.32–138.34) .03 Predicts perfectlya
Plasma non-HDL cholesterol level 14.9 mmol/Lb 5.50 (1.52–19.94) .009 2.94 (0.67–12.89) .15
Plasma triglyceride level 12.26 mmol/Lb 3.49 (0.83–14.72) .09 2.98 (0.56–15.75)c .20
Hypertension 2.39 (0.83–6.91) .10 1.56 (0.44–5.50)c .69
Metabolic syndrome 2.58 (0.88–7.60) .08 2.12 (0.59–7.60)c .25
Exposure to PI (per additional year) 1.03 (0.91–1.17) .63 …
Family history of cardiovascular disease 2.55 (0.84–7.75) .10 3.19 (0.87–11.69)c .08
HIV load !400 copies/mL 1.50 (0.39–5.79) .56 …
CD4+ T cell count !200 cells/mL 7.1 (1.09–46.24) .04 27.2 (2.55–286.01)c .006
Presumed duration of HIV infection (per additional year) 1.01 (0.91–1.12) .84 …
HIV clinical stage B 1.25 (0.34–4.64) .74 …
HIV clinical stage C 1.67 (0.48–5.82) .43 …
NOTE. PAD, peripheral arterial disease; PI, protease inhibitor.
a Because of 1 missing value, all diabetic patients included in the multivariable analysis had PAD, providing a perfect prediction.
b Sustained lipid levels (see Methods).
c Factors individually analyzed in models including 4 variables (with sex, age, and smoking).
or inflammatory, may be the causative mechanism. These an-
eurysms may have preferentially affected children in the era
before combination antiretroviral therapy was available, be-
cause of their presumable exposure to prolonged viremia, re-
sulting in large vessel vasculitis. More recently, Solages et al.
[39] also found a correlation between high HIV load and en-
dothelial dysfunction, supporting this hypothesis. However, in
many survivors from the era before combination antiretroviral
therapy, the HIV load is now controlled by HAART. This may
explain why the most recent HIV load did not correlate with
PAD in our study. However, low CD4+ T cell counts were
strongly associated with PAD in our study (OR, 27.2; Pp
). Such an association has previously been reported by.006
Mercie´ et al. [30], but the underlying mechanism is not clear.
Low CD4+ T cell counts may reflect the duration and severity
of uncontrolled HIV infection and be a surrogate marker of
potential endothelial toxicity of HIV. The association of PAD
with low CD4+ T cell count may also be partially confounded
by patient age, because older age is a predictor of a less robust
increase in CD4+ T cell counts after the introduction of anti-
retroviral therapy.
This study evaluated the feasibility of identifying patients
with PAD using a reliable test, the ABI. Although the ABI
measurements were performed by 3 vascular specialists in this
study, we previously demonstrated that ABI testing can be easily
performed by primary care physicians after minimal training
[40]. Because large-scale studies of ABI testing in the general
population have shown increased vascular and nonvascular
mortality for patients with an ABI of !0.90 [13–15, 28], this
is a call for widespread use of ABI testing in the HIV–infected
middle-aged population. Identification of persons with PAD by
ABI testing could serve to promote aggressive efforts at car-
diovascular risk reduction, particularly smoking cessation.
This study identified a high prevalence of symptomatic and
asymptomatic PAD in HIV-infected patients and suggests the
presence of an epidemic of PAD ∼20 years earlier in this pop-
ulation than in the general population. Patients can be easily
and reliably identified by ABI testing, and they presumably are
at increased cardiovascular risk, assuming that ABI mortality
correlations from the general population can be extrapolated
to HIV-infected persons. However, this pilot study is limited
by its small sample size, and larger studies are required to better
characterize risk factors for PAD and its prognosis in this
population.
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